Resistance to immune checkpoint therapies by tumour-induced T-cell desertification and exclusion: key mechanisms, prognostication and new therapeutic opportunities

Immune checkpoint therapies (ICT) can reinvigorate the effector functions of anti-tumour T cells, improving cancer patient outcomes. Anti-tumour T cells are initially formed during their first contact (priming) with tumour antigens by antigen-presenting cells (APCs). Unfortunately, many patients are...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Mona Meng, Coupland, Sarah E., Aittokallio, Tero, Figueiredo, Carlos R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10575907/
https://www.ncbi.nlm.nih.gov/pubmed/37454231
http://dx.doi.org/10.1038/s41416-023-02361-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10575907/
https://www.ncbi.nlm.nih.gov/pubmed/37454231
http://dx.doi.org/10.1038/s41416-023-02361-4

Ejemplares similares